359 related articles for article (PubMed ID: 29922039)
1. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.
Sui JD; Wang Y; Wan Y; Wu YZ
Drug Des Devel Ther; 2018; 12():1645-1657. PubMed ID: 29922039
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Nishino M; Giobbie-Hurder A; Hatabu H; Ramaiya NH; Hodi FS
JAMA Oncol; 2016 Dec; 2(12):1607-1616. PubMed ID: 27540850
[TBL] [Abstract][Full Text] [Related]
3. The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis.
Shi Z; Liu X; Chen M; Zhang N; Guan H; Ye D
Medicine (Baltimore); 2022 Dec; 101(52):e32393. PubMed ID: 36596018
[TBL] [Abstract][Full Text] [Related]
4. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
5. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Zhou JX; Feng LJ; Zhang X
Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
[TBL] [Abstract][Full Text] [Related]
6. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
7. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
9. Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials.
Hou J; Xie R; Zhang Z; Liu Q; Xiang Q; Cui Y
Front Pharmacol; 2023; 14():1163971. PubMed ID: 37033653
[No Abstract] [Full Text] [Related]
10. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Wang Y; Zhou S; Yang F; Qi X; Wang X; Guan X; Shen C; Duma N; Vera Aguilera J; Chintakuntlawar A; Price KA; Molina JR; Pagliaro LC; Halfdanarson TR; Grothey A; Markovic SN; Nowakowski GS; Ansell SM; Wang ML
JAMA Oncol; 2019 Jul; 5(7):1008-1019. PubMed ID: 31021376
[TBL] [Abstract][Full Text] [Related]
11. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
[TBL] [Abstract][Full Text] [Related]
12. Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials.
Wei W; Luo Z
Medicine (Baltimore); 2017 Dec; 96(48):e8931. PubMed ID: 29310385
[TBL] [Abstract][Full Text] [Related]
13. Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis.
Jiang X; Xiong F; Fu Q; Peng H; Jing Y; Rexiti K; Wei X; Tao S
Int J Colorectal Dis; 2022 Jul; 37(7):1525-1534. PubMed ID: 35780257
[TBL] [Abstract][Full Text] [Related]
14. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis.
Petrelli F; Ardito R; Borgonovo K; Lonati V; Cabiddu M; Ghilardi M; Barni S
Eur J Cancer; 2018 Nov; 103():7-16. PubMed ID: 30196108
[TBL] [Abstract][Full Text] [Related]
15. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
Schutz FA; Je Y; Choueiri TK
Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
[TBL] [Abstract][Full Text] [Related]
16. The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis.
Su Q; Zhang XC; Wang DY; Zhang HR; Zhu C; Hou YL; Liu JL; Gao ZH
Int Immunopharmacol; 2018 Jun; 59():328-338. PubMed ID: 29679857
[TBL] [Abstract][Full Text] [Related]
17. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
18. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
19. Toxicities associated with immune checkpoint inhibitors: a systematic study.
Kong X; Chen L; Su Z; Sullivan RJ; Blum SM; Qi Z; Liu Y; Huo Y; Fang Y; Zhang L; Gao J; Wang J
Int J Surg; 2023 Jun; 109(6):1753-1768. PubMed ID: 37132038
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis.
Man J; Ritchie G; Links M; Lord S; Lee CK
Asia Pac J Clin Oncol; 2018 Jun; 14(3):141-152. PubMed ID: 29349927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]